Business
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 6, 2018\n\n\n\nPublication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model \n\nCSE: IN OTCQB: IMLFF\n\n\n\nVANCOUVER, March 6, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of a peer-reviewed article in Drug Delivery and Translational Research.\n\nThe article, titled \"A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery\", presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed's Chief Scientific Officer.\n\nIn October, 2017, InMed originally announced completion of this study.  These proprietary data support what the Company believes to be a first-in-class nanoparticle-hydrogel formulation for cannabinoid delivery to the eye, resulting in enhanced drug uptake via the cornea and lens.  The patent family for this discovery is currently at the provisional stage and will be converted to a PCT filing during 2018. \n\n\"We are highly encouraged by the findings from our discovery, and are now pleased to see our research receiving acceptance from a key peer-reviewed journal\", said Dr. Hossain.  \"These study results demonstrate significant delivery of cannabinoids to the eye via transcorneal penetr...